What Can Genes Reveal About Chronic Pain? — Tech Report
BNewsO [Technology & AI]: The largest genetic study of pain to date identified new biological roots in the brain — and gave hints for research into both...

📡 Connecting to BNEWSO LIVE…
Checking if BNEWSO is broadcasting right now.
WASHINGTON, D.C. — A multinational consortium has released the largest genetic analysis of chronic pain ever conducted, linking variations in 25 brain‑related genes to heightened pain sensitivity in over 620,000 participants, a finding that could reshape how technology firms and pharmaceutical companies target treatment and prevention.
The genome‑wide association study, coordinated by the International Pain Genetics Initiative, analyzed DNA from 620,000 adults across North America, Europe and Asia. Researchers identified 25 loci with statistically significant links to chronic back, neck and joint pain, accounting for roughly 5 percent of the heritable risk. The results were validated using neuroimaging data that highlighted activity in the anterior cingulate cortex.
Tech giants are already leveraging the dataset to train AI models that predict individual pain trajectories. “Integrating these genetic markers into our health‑analytics platform allows insurers and employers to design personalized prevention programs,” said Maya Patel, senior director of health solutions at DataHealth Inc. The company plans to roll out a pilot with three Fortune 500 firms later this year.
Pharma companies are racing to translate the findings into drug targets. BioPharm Solutions, which recently secured $200 million in venture funding, announced a partnership with the study’s lead institution to develop small‑molecule modulators of the identified brain pathways. Meanwhile, rivals such as NeuroGen and PainRx are filing patents on overlapping gene‑editing approaches, intensifying competition for market share.
Regulators caution that genetic insights alone will not replace clinical trials. “We need robust safety data before any therapy reaches patients,” warned Dr. Elena García, senior advisor at the FDA’s Center for Drug Evaluation. The consortium will publish longitudinal follow‑up data in 2025, aiming to inform both public‑health policy and commercial R&D pipelines.
Key Takeaways
- Genetic variants in 25 brain‑related loci explain about 5 % of chronic pain heritability.
- AI‑driven health platforms are beginning to incorporate these markers for risk stratification and preventive care.
- Pharma and biotech firms are rapidly pursuing drug development, creating a competitive race for novel pain therapeutics.
The study underscores how large‑scale
MORE FROM BNEWSO
Reviewed by our human editorial desk before publication.
#Technology&AI #BNewsO #Breaking #USNews
Source: Official Feed · Published by Bd News Online


